First Report of OXA-48 and IMP Genes Among Extended-Spectrum Beta-Lactamase-Producing Escherichia coli Isolates from Diarrheic Calves in Tunisia
Microbial Drug Resistance · 2023
DOI: 10.1089/mdr.2022.0129 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbial Drug Resistance, 2023. Verfasst von Asma Ben Haj Yahia und 6 weiteren Autor:innen. Beteiligte Einrichtung: Service de Microbiologie et d'Immunologie, Ecole Nationale de Médecine Vétérinaire, University of Manouba, Sidi Thabet, Tunisie. Hauptthemen laut MEDLINE: Escherichia coli Infections, Anti-Infective Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 83 Literaturangaben.
Abstract (Originalsprache)
Antimicrobial resistance is one of the most serious threats to human and animal health. Evidence suggests that the overuse of antimicrobial agents in animal production has led to the emergence and dissemination of multidrug-resistant isolates. The objective of this study was to assess the rate of extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli in calf feces and to characterize their resistance genes for antibiotics like beta-lactams and colistin, but also to determine their virulence genes. Fecal samples were collected from 100 diarrheic calves in the region of Bizerte, Tunisia. After isolation, E. coli isolates were screened for antimicrobial resistance against 21 antibiotics by the disc diffusion method. Characterization of β-lactamase genes and determination of associated resistance genes were performed by polymerase chain reaction. Among 71 E. coli isolates, 26 (36.6%) strains were ESBL-producing. Most of these isolates were multidrug-resistant (92.3%) and the most prevalent beta-lactamase genes detected were bla CTX-M ( n = 26), bla SHV ( n = 11), and bla TEM ( n = 8), whereas only 1 isolate carried the bla CMY gene. In addition, resistance to carbapenems was detected in two isolates; one of them harbored both bla OXA-48 and bla IMP genes and the other isolate carried only the bla IMP gene. Several resistance genes were identified for the first time in Tunisia from cases of diarrheic calves. Furthermore, to the best of our knowledge, this is the first report of detection and identification of carbapenem resistance genes and virulence genes from calves in North Africa. A high occurrence of antimicrobial resistance of E. coli recovered from fecal samples of calves with diarrhea was observed, highlighting the need for prudent use of antimicrobial agents in veterinary medicine to decrease the incidence of multidrug-resistant bacteria for both animals and humans.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Service de Microbiologie et d'Immunologie, Ecole Nationale de Médecine Vétérinaire, University of Manouba, Sidi Thabet, Tunisie.
- Laboratoire des Microorganismes et Biomolécules Actives, Faculté des Sciences de Tunis, University of Tunis El Manar, Tunis, Tunisie.
- Office des Terres Domaniales, Agrocombinat Ghezala, Mateur, Tunisie.
ORCID-Profile: Ghassan Tayh
Zitieren
APA
Ben Haj Yahia, A., Tayh, G., Landolsi, S., Maamar, E., Galai, N., Landoulsi, Z., & Messadi, L. (2023). First Report of OXA-48 and IMP Genes Among Extended-Spectrum Beta-Lactamase-Producing Escherichia coli Isolates from Diarrheic Calves in Tunisia. Microbial Drug Resistance. https://doi.org/10.1089/mdr.2022.0129
Vancouver
Ben Haj Yahia A, Tayh G, Landolsi S, Maamar E, Galai N, Landoulsi Z, et al. First Report of OXA-48 and IMP Genes Among Extended-Spectrum Beta-Lactamase-Producing Escherichia coli Isolates from Diarrheic Calves in Tunisia. Microbial Drug Resistance. 2023. doi:10.1089/mdr.2022.0129
BibTeX
@article{BenHajYahia2023,
author = {Ben Haj Yahia, Asma and Tayh, Ghassan and Landolsi, Sarrah and Maamar, Elaa and Galai, Nejia and Landoulsi, Zbaida and Messadi, Lilia},
title = {First Report of OXA-48 and IMP Genes Among Extended-Spectrum Beta-Lactamase-Producing Escherichia coli Isolates from Diarrheic Calves in Tunisia},
journal = {Microbial Drug Resistance},
year = {2023},
doi = {10.1089/mdr.2022.0129}
}
EUVIMED